SCHEMBL1366255

SCHEMBL1366255

COc1ccc(C=CC(=O)CC(=O)c2cc3cc(I)ccc3oc2=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.52
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 2/20 0.51
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA3 P07451 1/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
GAA P10253 1/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.50
MAOB P27338 5/20 0.49
THRB P10828 1/20 0.48
MAOA P21397 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1366252 1.00 GSK3B (0.52) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1368523 1.00 GSK3B (0.52) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1368280 0.92 GSK3B (0.52) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1368282 0.92 GSK3B (0.52) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1368879 0.92 GSK3B (0.52) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1366983 0.88 POLB (0.62) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1367464 0.88 KMT2A (0.61) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1367668 0.88 KMT2A (0.61) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1366982 0.88 POLB (0.62) GSK3BKDM4EALDH1A1HPGDCA12
SCHEMBL1367924 0.88 POLB (0.62) GSK3BKDM4EALDH1A1HPGDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS GSK3B 4183/4885KDM4E 2293/4885ALDH1A1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.